Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
2 competitors in Influenza, Human
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Dectova
Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ?6 months) when: The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or Other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient. Dectova should be used in accordance with official guidance.
View on EMAHepatitis B
Infections, Meningococcal
Pulmonary Disease, Chronic Obstructive
Dental Caries
Haemophilus Influenzae Type b